Sharekhan

Sequent Scientific Ltd

Thu 11/09/2025,11:49:59 NSE: SEQUENT

₹ 184.07 0.90 (0.49%)
BUY NOW Buy Sequent Scientific Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Sequent Scientific Ltd

Thu 11/09/2025,12:3:0

Sequent Scientific Ltd

Thu 11/09/2025,11:49:59 | NSE : SEQUENT

₹ 184.070.90 (0.49%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 183.50

Previous Close

₹ 183.17

Volume

183677

Mkt Cap ( Rs. Cr)

₹4607.36

High

₹ 186.88

Low

₹ 183.00

52 Week High

₹ 240.70

52 Week Low

₹ 117.35

Book Value Per Share

₹ 27.16

Dividend Yield

0.00

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Sequent Scientific Ltd

Your Vote -

Buy

87.54%

Hold

6.28%

Sell

6.18%

87.54%

12639 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

17%

Sell Order Quantity

83%

Bid Price

Qty

184.64

17

185.00

27

185.00

26

185.00

41

185.00

79

Bid Total

44615

Bid Price

Qty

184.86

6

185.00

41

185.00

59

185.00

27

185.00

22

Bid Total

213939

Option Chain

Analyzes market sentiment, predicts Sequent Scientific Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Sequent Scientific - Announcement under Regulation 30 (LODR)-Resignation of Director

    10 Sep 2025, 6:44PM Resignation of Mr. Vedprakash Ragate , Re-submitting with resignation letter as Annexure -B

  • Sequent Scientific - Announcement under Regulation 30 (LODR)-Resignation of Director

    10 Sep 2025, 6:21PM Resignation of Mr. Vedprakash Ragate

  • Sequent Scientific - Analysts/Institutional Investor Meet/Con. Call Updates

    13 Aug 2025, 6:07PM Sequent Scientific Limited has informed the Exchange about Transcript

  • Sequent Scientific - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    13 Aug 2025, 6:00PM Earnings call Transcript

  • Sequent Scientific - Analysts/Institutional Investor Meet/Con. Call Updates

    13 Aug 2025, 12:46PM Sequent Scientific Limited has informed the Exchange about Transcript

  • Sequent Scientific - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    13 Aug 2025, 12:56PM Earning call Transcript

  • Sequent Scientific - Analysts/Institutional Investor Meet/Con. Call Updates

    11 Aug 2025, 11:49AM Sequent Scientific Limited has informed the Exchange about Link of Recording

  • Sequent Scientific - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    11 Aug 2025, 11:45AM Audio Recording of Earnings call pertaining to the Unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2025

  • Sequent Scientific - Copy of Newspaper Publication

    9 Aug 2025, 9:27PM Sequent Scientific Limited has informed the Exchange about Copy of Newspaper Publication

  • Sequent Scientific - Shareholders meeting

    8 Aug 2025, 9:19PM Sequent Scientific Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 08, 2025. Further, the company has

  • Sequent Scientific - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    8 Aug 2025, 9:16PM Voting Results and Scrutinizer's Report for 40th Annual General Meeting.

  • Sequent Scientific - Shareholders meeting

    8 Aug 2025, 7:48PM Summary of Proceedings of the 40th Annual General Meeting of the Companyheld on Friday, August 8, 2025

  • Sequent Scientific - Shareholder Meeting / Postal Ballot-Outcome of AGM

    8 Aug 2025, 7:44PM Summary of Proceeding of the 40th Annual General Meeting of the Company held on Friday, August 8, 2025

  • Sequent Scientific - Announcement under Regulation 30 (LODR)-Change in Directorate

    8 Aug 2025, 5:46PM Proposed change in Management

  • Sequent Scientific - Outcome of Board Meeting

    8 Aug 2025, 5:37PM Sequent Scientific Limited has informed the Exchange regarding Board meeting held on August 08, 2025.

  • Sequent Scientific Q1 net profit down 25.11% at Rs 3.37 cr

    8 Aug 2025, 1:20PM The company reported standalone net profit of Rs 3.37 crore for the quarter ended June 30, 2025 as compared to Rs 4.50 crore in the same period last y

  • Sequent Scientific - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    8 Aug 2025, 1:06PM Press Release & Investor presentation for Q1 FY 26

  • Sequent Scientific - Analysts/Institutional Investor Meet/Con. Call Updates

    8 Aug 2025, 1:03PM Sequent Scientific Limited has informed the Exchange about Presentation

  • Sequent Scientific - Outcome of Board Meeting

    8 Aug 2025, 12:54PM Sequent Scientific Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.

  • Sequent Scientific - Unaudited Standalone & Consolidated Financial Results For The Quarter Ended June 30, 2025

    8 Aug 2025, 12:49PM Financial Results for Q1 FY26

  • Sequent Scientific - Board Meeting Outcome for Outcome Of Board Meeting Held On Friday, August 08, 2025, Along With Unaudited

    8 Aug 2025, 12:44PM Outcome of Board Meeting held on Friday, August 08, 2025, along with Unaudited Standalone & Consolidated Financial Results for the quarter ended June

  • Sequent Scientific - Outcome of Board Meeting

    8 Aug 2025, 12:41PM Sequent Scientific Limited has informed the Exchange regarding Board meeting held on August 08, 2025.

  • Sequent Scientific - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    8 Aug 2025, 9:16PM Voting Results and Scrutinizer's Report for 40th Annual General Meeting.

  • Sequent Scientific - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    8 Aug 2025, 9:16PM Voting Results and Scrutinizer's Report for 40th Annual General Meeting.

  • Sequent Scientific - Analysts/Institutional Investor Meet/Con. Call Updates

    5 Aug 2025, 5:27PM Sequent Scientific Limited has informed the Exchange about Schedule of meet

  • Sequent Scientific - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    5 Aug 2025, 5:26PM Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of\r\nIndia (Listing Obligations and Disclosure Requir

  • Sequent Scientific - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29(1) Of The SEBI (Listing Obl

    31 Jul 2025, 5:30PM Sequent Scientific Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2025 ,inter alia, to consider a

  • Sequent Scientific - Copy of Newspaper Publication

    29 Jul 2025, 5:29PM Sequent Scientific Limited has informed the Exchange about Copy of Newspaper Publication

  • Sequent Scientific - Disclosure Under Regulations 30 Of The Securities And Exchange Board Of India (Listing Obligations And D

    28 Jul 2025, 9:05PM Notice of NCLT Convened Meeting

  • Sequent Scientific - Shareholders meeting

    28 Jul 2025, 9:02PM Sequent Scientific Limited has informed the Exchange about Shareholders meeting

  • Sequent Scientific has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2025

    22 Jul 2025, 7:06AM As of June 2025, 52.61% is owned by Foreign Promoters and 47.23% by Public. <p align=justify> Top two Promoters holding highest number of shares of Se

  • Sequent Scientific - Announcement Under Regulation 30 -Update

    18 Jul 2025, 7:56PM Announcement under Regulation 30-Update

  • Sequent Scientific - Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

    18 Jul 2025, 7:53PM Sequent Scientific Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

  • Sequent Scientific - Copy of Newspaper Publication

    17 Jul 2025, 6:52PM Sequent Scientific Limited has informed the Exchange about Copy of Newspaper Publication

  • Sequent Scientific - Notice Of Shareholders Meetings-XBRL

    16 Jul 2025, 8:55PM SEQUENT SCIENTIFIC LIMITED has informed the Exchange about Notice of Shareholders Meeting for Annual General Meeting to be held on 08-Aug-2025

  • Sequent Scientific - Updates

    16 Jul 2025, 7:30PM Sequent Scientific Limited has informed the Exchange regarding 'Letter To The Shareholders - Annual Report F.Y. 2024-25 '.

  • Sequent Scientific - Letter To The Shareholders - Annual Report F.Y. 2024-25

    16 Jul 2025, 7:27PM Letter to the Shareholder -Annual Report F.Y. 2024-25

  • Sequent Scientific - Reg. 34 (1) Annual Report.

    16 Jul 2025, 7:17PM Annual Report for the FY 2024-25

  • Sequent Scientific - Updates

    16 Jul 2025, 6:43PM Sequent Scientific Limited has informed the Exchange regarding 'BRSR Report '.

  • Sequent Scientific - Shareholders meeting

    16 Jul 2025, 6:29PM Sequent Scientific Limited has informed the Exchange about Shareholders meeting

  • Sequent Scientific - Business Responsibility and Sustainability Reporting (BRSR)

    16 Jul 2025, 6:14PM Business Responsibility and Sustainability Reporting

  • Sequent Scientific - Notice Of 40Th Annual General Meeting Scheduled On August 08, 2025.

    16 Jul 2025, 6:05PM Notice of 40th Annual General Meeting scheduled on August 08, 2025.

  • Sequent Scientific - Copy of Newspaper Publication

    16 Jul 2025, 1:08PM Sequent Scientific Limited has informed the Exchange about Copy of Newspaper Publication

  • Sequent Scientific - Reg. 34 (1) Annual Report.

    16 Jul 2025, 5:58PM Annual Report for the FY 2024-25

  • Sequent Scientific - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    14 Jul 2025, 7:49PM SEQUENT SCIENTIFIC LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer

  • Sequent Scientific - General Updates

    14 Jul 2025, 11:32AM Sequent Scientific Limited has informed the Exchange about General Updates

  • Sequent Scientific - Re-Appointment Of Non-Executive Independent Directors.

    14 Jul 2025, 11:21AM Re-appointment of Non-Executive Independent Director.

  • Sequent Scientific - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    8 Jul 2025, 5:25PM Sequent Scientific Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Sequent Scientific - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    8 Jul 2025, 5:35PM Compliance certificate under Reg 74 (5) of SEBI (DP) Regulation, 2018.

  • Sequent Scientific - Disclosure under SEBI Takeover Regulations

    30 Jun 2025, 9:14PM CA Harbor Investments has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substan

  • Sequent Scientific - General Updates

    26 Jun 2025, 3:58PM Sequent Scientific Limited has informed the Exchange about General Updates

  • Sequent Scientific - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    26 Jun 2025, 3:51PM Allotment of ESOP

  • Sequent Scientific - Trading Window

    25 Jun 2025, 6:25PM Sequent Scientific Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulation

  • Sequent Scientific - Trading Window-XBRL

    25 Jun 2025, 6:22PM SEQUENT SCIENTIFIC LIMITED has informed the Exchange about Closure of Trading Window

  • Sequent Scientific - General Updates

    18 Jun 2025, 12:03PM Sequent Scientific Limited has informed the Exchange about General Updates

  • Sequent Scientific - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    18 Jun 2025, 12:05PM Allotment of ESOP

  • Sequent Scientific

    9 Mar 2023 , 10:17AM The transaction contemplated under the agreement to acquire 100% stake in Tineta Pharma has not been materialised, and the acquisition will not happen. Positive read through.

  • Sequent Scientific

    17 Jan 2022 , 10:45AM The board of directors have appointed Mr Rajaram Narayanan as the MD and CEO of the company effective 11 April 2022. Mr. Narayanan, who has served in senior leadership roles across the pharmaceutical, consumer goods and services industries and has a strong track record of leading revenue and profitability growth across multiple industries including pharmaceuticals. This bodes well for Sequent Scientific from a growth perspective, Positive.

  • Sequent Scientific signs agreement to buy Brazilian animal healthcare co

    16 Dec 2021 , 12:25PM Sequent Scientific signs definitive agreement to acquire stake in Nourrie Saude e Nutricao Animal Ltda

  • SeQuent Scientific

    15 Jul 2021 , 9:39AM Announced the EUGMP approval of its tablets dosage manufacturing line in Turkey. The approval was further complimented by the successful renewal of EUGMP license for 8 other manufacturing lines for various dosage forms in Turkey. In addition to the EUGMP, the manufacturing lines in Turkey also hold GMP certificates from Turkish, Saudi, Ethiopian and Sudanese authorities. Overall the company has 120 products registered and is the third largest player in Turkey ruminant market with a consolidated market share of 10%. The EUGMP approval is positive as it would enable the company to cater to regulated market of Europe.

  • SeQuent announces launch of Citramox LA in EU

    10 Dec 2020 , 3:09PM SeQuent Scientific launches Citramox LA 150 mg/ml Suspension Injection for Cattle and Pigs in 10 European countries

  • SeQuent announces launch of inhouse developed Halofusol in EU

    1 Dec 2020 , 12:26PM SeQuent Scientific launches Halofusol oral solution for calves in 19 European countries

  • Sequent Scientific signs agreement for acquisition of 40% stake in Provet

    23 Sep 2020 , 11:22AM Sequent Scientific enters into definitive agreement with Dr. Huseyin Aydin for the acquisition of 40% stake in Provet Veteriner Urunleri San. Ve Tic. A

  • Sequent Scientific Ltd

    11 May 2020 , 12:47PM Enters into Binding Agreements to Acquire a Majority Stake in SeQuent Scientific Ltd; Mandatory open offer to trigger at Rs 86 per share, a premium of ~7% over 8th May 2020 closing price

  • SeQuent Scientific receives EIR from USFDA

    20 Aug 2019 , 2:19PM SeQuent Scientific receives EIR from USFDA for its Analytical Laboratory at Bengaluru
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Sequent Scientific Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 1187.034 1133.683 1077.461 1056.588 1034.728
Liabilities 1187.034 1133.683 1077.461 1056.588 1034.728
Equity 50.06 49.886 49.887 49.674 49.674
Gross Profit -11.383 -26.664 -26.36 -0.75 35.29
Net Profit 15.794 0.622 -6.08 14.799 32.113
Cash From Operating Activities -1.125 -26.944 37.746 9.364 2.338
NPM(%) 8.86 0.36 -2.73 6.73 12.09
Revenue 178.257 168.518 222.685 219.626 265.457
Expenses 189.64 195.182 249.045 220.376 230.167
ROE(%) 2.32 0.09 -0.89 2.17 4.72

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
08 Sep 2021 0.5 25 0 283.05
21 Aug 2019 0.2 10 0 68.05
20 Nov 2017 0.2 10 0 100.1

Peers

Other companies within the same industry or sector that are comparable to Sequent Scientific Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 810.00 0.77 73.44 104.73 301.39 0.62
Lotus Eye Hospital and Institute Ltd 121.90 0.42 393.23 381.61 3.55 0.00
Vaishali Pharma Ltd 12.09 0.33 403.00 196.70 3.13 0.00
Astec Lifesciences Ltd 857.00 0.53 0.00 359.87 -604.77 0.00

Company Info

2003 - Hon'ble High Court of Bombay approved the Scheme of Amalgamation of company with P I Drugs & Pharmaceuticals Ltd. 2007 -PI Drugs & Pharmaceuticals Ltd has informed that Dr. Gopakumar G Nair has joined the Board as Independent Director effective June 20, 2007. 2008 - PI Drugs Board recommends dividend @ 10% 2009 - PI Drugs & Pharmaceuticals Ltd equity shareholders approve Scheme of Amalgamation - PI Drugs & Pharmaceuticals Ltd Board recommends Dividend@ 10% - PI Drugs & Pharmaceuticals Ltd - Change of name of the Company from PI Drugs & Pharmaceuticals Ltd to Sequent Scientific Ltd. 2010 - SeQuent Scientific to invest Rs. 150 crore in three new therapeutic segments - Signs an MoU with Karnataka Government. 2011 - PI Drugs & Pharmaceuticals Ltd Appoined Mr. Vinayak Hegde as Company Secretary . 2012 - PI Drugs - Issue of Warrants on Preferential basis - PI Drugs - Alloted 10,00,000 fully paid equity shares of Rs. 10/- each --Registered Office of the Company has been shifted from No. 116, Vardhaman Industrial Complex, Lal Bahaddur Shastri Marg, Thane west - 400 601 to 301, 'Dosti Pinnacle', 3rd Floor, Plot No. E7, Road No. 22, Wagle Indl. Estate, Thane (W) - 400 604. 2013 -Sequent receives US FDA Approval for ITS API Drug Manufacturing Facility at Mangalore. -Sequent Scientific Ltd & Shasun Pharmaceuticals Ltd announce Joint Venture to Create Leading Animal Health Company. 2014 -SeQuent Scientific Limited announces completion of Sale of Specialty Chemicals division to Songwon Industrial Group. -Sequent Scientific to acquire the business of Arvee Synthesis Acquisition to provide impetus to Human API business. -Sequent Scientific - Updates - Alivira completes acquisition of majority stake in Provet Veterinary Products AS, Turkey. 2015 -SeQuent Scientific to acquire Animal Health business of Lyka Exports -SeQuent Scientific inaugurates new Analytical Services Centre at Bengaluru 2016 - SeQuent Scientific to acquire controlling stake in Indo Phyto Chemicals Forays into steroids and hormone -Sequent Scientific commences production in Vizag facility 2017 -SeQuent Scientific said that , its arm Alivira has received approval from the US health regulator for its animal health API facility in Visakhapatnam in Andhra Pradesh. 2018 -SeQuent Scientific Limited (SeQuent), has said that its wholly owned subsidiary Alivira Animal Health Limited (“Alivira”) through Alivira Ireland, has signed an agreement with simultaneous closing to acquire 100 per cent of Bremer Pharma, Zydus Cadila’s Animal Health Business in Germany . 2020 -Sequent Scientific announces addition of new state-of-art Animal Health R&D Centre at Mumbai -SeQuent Scientific receives EIR from US FDA for its Analytical Laboratory at Bengaluru 2021 -Sequent Scientific forays into pet segment in Brazil -The company has said that Evance Saude Animal Health Ltda ('Evance'), Brazil, a subsidiary of the Company has entered into a definitive agreement for acquisition of 100% stake in Nourrie Sa£de e Nutri‡ao Animal Ltda ('Nourrie').\r\n\r\nIn this regard, -SeQuent Scientific Limited (SeQuent) has said that European Union Good Manufacturing Practices (EUGMP) approval of its tablets dosage manufacturing line in Turkey. -SeQuent received CEP approval for Diclazuril API

2003 - Hon'ble High Court of Bombay approved the Scheme of Amalgamation of company with P I Drugs & Pharmaceuticals Ltd. 2007 -PI Drugs & Pharmaceuticals Ltd has informed that Dr. Gopakumar G Nair has joined the Board as Independent Director effective June 20, 2007. 2008 - PI Drugs Board recommends dividend @ 10% 2009 - PI Drugs & Pharmaceuticals Ltd equity shareholders approve Scheme of Amalgamation - PI Drugs & Pharmaceuticals Ltd Board recommends Dividend@ 10% - PI Drugs & Pharmaceuticals Ltd - Change of name of the Company from PI Drugs & Pharmaceuticals Ltd to Sequent Scientific Ltd. 2010 - SeQuent Scientific to invest Rs. 150 crore in three new therapeutic segments - Signs an MoU with Karnataka Government. 2011 - PI Drugs & Pharmaceuticals Ltd Appoined Mr. Vinayak Hegde as Company Secretary . 2012 - PI Drugs - Issue of Warrants on Preferential basis - PI Drugs - Alloted 10,00,000 fully paid equity shares of Rs. 10/- each --Registered Office of the Company has been shifted from No. 116, Vardhaman Industrial Complex, Lal Bahaddur Shastri Marg, Thane west - 400 601 to 301, 'Dosti Pinnacle', 3rd Floor, Plot No. E7, Road No. 22, Wagle Indl. Estate, Thane (W) - 400 604. 2013 -Sequent receives US FDA Approval for ITS API Drug Manufacturing Facility at Mangalore. -Sequent Scientific Ltd & Shasun Pharmaceuticals Ltd announce Joint Venture to Create Leading Animal Health Company. 2014 -SeQuent Scientific Limited announces completion of Sale of Specialty Chemicals division to Songwon Industrial Group. -Sequent Scientific to acquire the business of Arvee Synthesis Acquisition to provide impetus to Human API business. -Sequent Scientific - Updates - Alivira completes acquisition of majority stake in Provet Veterinary Products AS, Turkey. 2015 -SeQuent Scientific to acquire Animal Health business of Lyka Exports -SeQuent Scientific inaugurates new Analytical Services Centre at Bengaluru 2016 - SeQuent Scientific to acquire controlling stake in Indo Phyto Chemicals Forays into steroids and hormone -Sequent Scientific commences production in Vizag facility 2017 -SeQuent Scientific said that , its arm Alivira has received approval from the US health regulator for its animal health API facility in Visakhapatnam in Andhra Pradesh. 2018 -SeQuent Scientific Limited (SeQuent), has said that its wholly owned subsidiary Alivira Animal Health Limited (“Alivira”) through Alivira Ireland, has signed an agreement with simultaneous closing to acquire 100 per cent of Bremer Pharma, Zydus Cadila’s Animal Health Business in Germany . 2020 -Sequent Scientific announces addition of new state-of-art Animal Health R&D Centre at Mumbai -SeQuent Scientific receives EIR from US FDA for its Analytical Laboratory at Bengaluru 2021 -Sequent Scientific forays into pet segment in Brazil -The company has said that Evance Saude Animal Health Ltda ('Evance'), Brazil, a subsidiary of the Company has entered into a definitive agreement for acquisition of 100% stake in Nourrie Sa£de e Nutri‡ao Animal Ltda ('Nourrie').\r\n\r\nIn this regard, -SeQuent Scientific Limited (SeQuent) has said that European Union Good Manufacturing Practices (EUGMP) approval of its tablets dosage manufacturing line in Turkey. -SeQuent received CEP approval for Diclazuril API

Read More

Parent Organisation

Sequent Scientific Ltd.

Founded

28/06/1985

Managing Director

Mr.Rajaram Narayanan

NSE Symbol

SEQUENTEQ

FAQ

The current price of Sequent Scientific Ltd is ₹ 184.07.

The 52-week high for Sequent Scientific Ltd is ₹ 186.88 and the 52-week low is ₹ 183.00.

The market capitalization of Sequent Scientific Ltd is currently ₹ 4607.36. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Sequent Scientific Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Sequent Scientific Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Sequent Scientific Ltd shares.

The CEO of Sequent Scientific Ltd is Mr.Rajaram Narayanan, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT